Skip to main content

. 1988 Feb;57(2):198–200. doi: 10.1038/bjc.1988.42

Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test.

M Volm ¹, P Drings ¹, E W Hahn ¹, J Mattern ¹

PMCID: PMC2246447 PMID: 3358911

198

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bech-Hansen N. T., Till J. E., Ling V. Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol. 1976 May;88(1):23–31. doi: 10.1002/jcp.1040880104. [DOI] [PubMed] [Google Scholar]
GEHAN E. A. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika. 1965 Jun;52:203–223. [PubMed] [Google Scholar]
Legha S. S., Muggia F. M., Carter S. K. Adjuvant chemotherapy in lung cancer: review and prospects. Cancer. 1977 Apr;39(4):1415–1424. doi: 10.1002/1097-0142(197704)39:4<1415::aid-cncr2820390410>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
Mattern J., Volm M. Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treat Rev. 1982 Dec;9(4):267–298. doi: 10.1016/s0305-7372(82)80041-8. [DOI] [PubMed] [Google Scholar]
Salmon S. E., Hamburger A. W., Soehnlen B., Durie B. G., Alberts D. S., Moon T. E. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med. 1978 Jun 15;298(24):1321–1327. doi: 10.1056/NEJM197806152982401. [DOI] [PubMed] [Google Scholar]
Volm M. Use of tritiated nucleotide incorporation for prediction of sensitivity of tumors to cytostatic agents. Behring Inst Mitt. 1984 May;(74):273–284. [PubMed] [Google Scholar]
Volm M., Wayss K., Kaufmann M., Mattern J. Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer. 1979 Jul;15(7):983–993. doi: 10.1016/0014-2964(79)90282-2. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES